Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02809118Phase 3Terminated

Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment

Role: lead

NCT01803646Phase 3Completed

AM-101 in the Treatment of Acute Tinnitus 2

Role: lead

NCT01934010Phase 3Completed

AM-101 in the Treatment of Post-Acute Tinnitus 1

Role: lead

NCT01270282Phase 2Completed

Comparison of Single Versus Repeat Doses of AM-101 in the Treatment of Acute Inner Ear Tinnitus

Role: lead

All 4 trials loaded